Credit Suisse Group AG upgraded Esperion Therapeutics Inc (NASDAQ:ESPR) to Neutral in a report released today.
- Updated: March 20, 2017
Yesterday Esperion Therapeutics Inc (NASDAQ:ESPR) traded 52.64% higher at $36.19. The company’s 50-day moving average is $23.80 and its 200-day moving average is $15.00. The last closing price is up 140.83% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 9,355,593 shares of the stock traded hands, up from an average trading volume of 931,170
Credit Suisse Group AG has upgraded Esperion Therapeutics Inc (NASDAQ:ESPR) to Neutral in a report released on Monday March 20, 2017.
Previously on 2/28/2017, Citigroup Inc reported on Esperion Therapeutics Inc (NASDAQ:ESPR) increased the target price from $14.00 to $39.00. At the time, this indicated a possible upside of 0.25%.
See Chart Below
Esperion Therapeutics Inc has a 52 week low of $9.40 and a 52 week high of $37.16 Esperion Therapeutics Inc’s market capitalization is presently $0.
A total of 12 analysts have released a report on Esperion Therapeutics Inc. Three analysts rating the company a strong buy, eight analysts rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $32.67.
General Company Details For Esperion Therapeutics Inc (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.